2017-10-25 18:00:08

Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB (publ)

Related content
29 nov - 
Enzymatica AB: Enzymaticas valberedning för årsstämman ..
14 nov - 
Enzymatica AB: Enzymatica presenterar resultat av studi..
09 nov - 
Enzymatica AB: Studie om ColdZyme - Den mest rekommende..

Press release

25 October 2017

Bulletin from extraordinary general meeting in Enzymatica AB (publ)

Enzymatica held an extraordinary general meeting today on 25 October 2017 in Lund. The general meeting resolved upon the following:

Resolution on personnel option program

The extraordinary general meeting resolved in accordance with the proposal for resolution to adopt Personnel Option Program 2017/2023 II and resolution to issue directed warrants as well as approval of transfer of warrants. Personnel Option Program 2017/2023 II corresponds in all material respects with the terms and conditions for Personnel Option Program 2017/2023 as resolved by the annual general meeting on 20 April 2017 and the purpose for the implementation of Personnel Option Program 2017/2023 II is to enable additional employees to participate in an incentive program on equivalent terms. The program entails that a maximum of 1,390,000 personnel options shall be offered to a by the board elected circle of individuals between 25 October 2017 and 25 December 2017. The holders can utilize the allotted personnel options during the period from and including 1 May 2021 to and including 31 July 2023. Each personnel option confers a right to acquire one new share in the company against cash consideration at a utilization price of SEK 4.22, which corresponds to 150 percent of the average value of the Enzymatica share on Nasdaq First North during the period from and including 5 April 2017 to and including 19 April 2017. The personnel options shall be allotted without consideration and cannot be transferred.

In order to enable the delivery of shares as well as to hedge ancillary costs, primarily social security charges, a maximum of 1,826,738 warrants shall be issued to Enzymatica's wholly owned subsidiary Enzymatica Care AB which thereafter may be transferred to the participants without consideration in connection with the utilization of personnel options. The dilution effect of the program is approximately 2 percent. The maximum dilution effect of program 2017/2023 and program 2017/2023 II is approximately 5 percent of the company's share capital and votes.

Extended authorization of the board to issue new shares

The general meeting resolved to extend the existing authorization of the board to issue new shares, resolved by the annual general meeting in 2017, as regards reasons. The reason for deviation from the general preferential rights, in addition to enable the company to raise new capital and to take advantage of future opportunities to attract new long-term owners of strategic importance to the company, as well as to finance the company's growth strategy, is also to enable the company to acquire the remaining minority shares in the subsidiary Zymetech ehf. by issue in kind. In other respects, the authorization by the annual general meeting remains unaltered.

For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB

Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com   

About Enzymatica AB

Enzymatica AB is a life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in around ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information please visit: www.enzymatica.se

Enzymatica's Certified Adviser is Erik Penser Bank.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Enzymatica AB via Globenewswire

Postkommentar

Related debate

  • 1 vecka
  • 1 månad
  • 1 År
Ingen indlæg

Finansiell uppdatering för det fjärde kvartalet 2017

2018-01-17 08:30:03
Stockholm, 2018-01-17 08:30 CET (GLOBE NEWSWIRE) --   Lundin Petroleum AB (Lundin Petroleum) kommer att redovisa prospekteringskostnader om cirka 31 MUSD före skatt, en valutakursförlust om cirka 69 MUSD samt en förlust vid försäljning av tillgångar om 15 MUSD efter skatt för det fjärde kvartalet 2017.   Resultatet för det fjärde kvartalet 2017 kommer att påverkas av vissa prospekteringskostnader..

SEB: Fortsatt fallande boprisförväntningar bland hushållen

2018-01-15 08:30:09
SEB:s Boprisindikator forsätter att falla. Nedgången är 8 enheter jämfört med föregående månad och indikatorn hamnar nu på minus 13. Regionalt sticker Stockholm ut även denna månad jämfört med de övriga regionerna. Stockholm ligger lägst på minus 31 och övriga regioner i spannet 2 till minus 12. Hushållens förväntningar på reporäntans nivå om ett år stiger något jämfört med förra månaden frå..

Lindab International AB (publ): Ny koncernchef i Lindab

2018-01-12 07:40:14
Ola Ringdahl har av styrelsen i Lindab International AB utsetts till ny VD och koncernchef. Han kommer att ersätta Fredrik von Oelreich som sedan den 29 september 2017 är tillförordnad koncernchef. - Jag är mycket nöjd över att kunna presentera Ola Ringdahl som ny VD och koncernchef, säger styrelseordförande Peter Nilsson. Ola kommer genom sin kompetens och erfarenhet skapa framåtanda och ..

Mest lästa nyheter

  • 24 timmar
  • 48 timmar
  • 1 vecka
1
Rezidor Hotel Group presenterar sin 5-års plan vid investerardagen
2
SERSTECH AB: Serstech har fått sin första kund i Kina inom kvalitetskontroll
3
Hoylu AB: HOYLU OCH POLYMEDIA ERBJUDER PRODUKTLÖSNINGAR FÖR DEN VÄXANDE MARKNADEN FÖR SAMARBETE I RYSSLAND
4
Arc Aroma Pure AB : 180117 Arc Aroma Pure AB (publ) genomför en riktad kvittningsemission för ett lån om 17,5 MSEK
5
Klövern AB (publ): Klövern tecknar stamaktier i en riktad nyemission i Tobin Properties

Related stock quotes

Enzymatica AB 4,70 0,0% Aktiepriset oförändrad

Buy and sell signals

  • Trender
  • Pengamaskinen

Upphovsrätt Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Kursinformation levereras av Morningstar.
Alla kurser är fördröjda 15-20 minuter, enligt distributionsavtal fastställda av de olika börserna.
 
den 18 januari 2018 03:00:45
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180112.1 - EUROWEB5 - 2018-01-18 03:00:45 - 2018-01-18 03:00:45 - 2 - Website: OKAY